Evan Lippman's most recent trade in Teva- Pharmaceutical Industries Ltd. - ADR was a trade of 74,008 Restricted Share Units done . Disclosure was reported to the exchange on May 14, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Teva- pharma Ind Ltd (ADR) | Evan Lippman | EVP, Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2026 | 74,008 | 74,008 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Evan Lippman | EVP, Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2026 | 74,008 | 80,103 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Evan Lippman | EVP, Business Development | Sale of securities on an exchange or to another person at price $ 35.58 per share. | 14 May 2026 | 35,912 | 44,191 (0%) | 0% | 35.6 | 1,277,900 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Evan Lippman | EVP, Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2026 | 11,841 | 11,841 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Evan Lippman | EVP, Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2026 | 11,841 | 35,524 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Evan Lippman | EVP, Business Development | Sale of securities on an exchange or to another person at price $ 35.58 per share. | 14 May 2026 | 5,746 | 6,095 (0%) | 0% | 35.6 | 204,467 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Evan Lippman | EVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 27,347 | 27,347 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Evan Lippman | EVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 148,016 | 148,016 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Evan Lippman | EVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 47,365 | 47,365 | - | - | Restricted Share Units |